Cabaletta Bio, Inc. is a pre-clinical biotechnology company using proprietary technology to discover and develop chimeric autoantibody receptor, or CAAR, T cell product candidates for B cell-mediated autoimmune diseases. The Company’s initial therapeutic focus is on pemphigus vulgaris (PV), a chronic, blistering autoimmune disease. The Company’s lead candidate, DSG3-CAART, is being evaluated for the treatment of mucosal PV (mPV), a subtype of PV that affects mucosal surfaces and is caused by autoantibodies against the cell adhesion protein desmoglein 3 (DSG3). DSG3-CAART is designed to selectively target B cells expressing autoantibodies against DSG3, eliminating the cause of mPV while preserving normal immune function. Cabaletta’s second product candidate, DSG3/1-CAART, is designed to target B cells expressing autoantibodies against DSG3 and desmoglein 1 (DSG1) and is being developed for the treatment of mucocutaneous PV (mcPV), another subtype of PV.